Prostate Specific Antigen - Standard Grade

Added to your cart

Prostate Specific Antigen - Standard Grade

Cart subtotal: ¥0.00

View cart (0) Checkout

#SKU P117-8

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team

Product Details

Free-PSA has a molecular weight of 30 kDa and a pI of 6.2-6.5, while PSA-ACT molecular weight is 90 kDa (PSA 28kDa and ACT 60-65kDa). PSA is localised in cytoplasm of prostate acinar cells, ductal epithelium and seminal fluid. PSA exists in 3 major forms; free PSA, PSA-ACT (PSA bound to Alpha-1 Antichymotrypsin) and PSA-A2M (PSA bound to Alpha-2 Macroglobulin). Serum concentration as a free to bound ratio correlates well with tumour mass and clinical stage of prostate cancer. High levels of free PSA can also be seen in serum from patients with benign hypertrophy

More information



  • Shipping Information
  • Cool Pack
  • Abbreviations
  • PSA
  • Specification
  • >40%
  • Recommended Use
  • Research and further manufacturing
  • Preservatives
  • 0.09% NaN3
  • Buffer
  • 0.05M phosphate buffer, pH 7.5 containing 0.15M NaCl
  • Presentation Matrix
  • Liquid in 0.05M phosphate buffer, pH 7.5 containing 0.15M NaCl and 0.09% NaN3
  • Purity/grade
  • >40%
  • Source
  • Seminal Fluid
  • Applications
  • Biosensors, Clinical Chemistry, Control Manufacture, ELISA, Lateral Flow, Life Science
  • Molecular weight
  • ~30kDa

Technical Documents

Certificates Of Analysis (102.63KB)

Safety Data Sheet (41.65KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands


The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.


Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.


Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox